leisure time -WSS

leisure time

author：explore 2025-10-01 11:00:02 - browse：8

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

WSS

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

He's 19 months old and has one of the world’s rarest diseases

Pregnant women don't need prenatal multivitamins, study concludes

Fetal cell organoids grown from amniotic fluid, study finds

For AI in health care standards, federal regulators join with industry group

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Study suggests Covid rebound is far more common with Paxlovid than without

Psychedelics group wrestles with new pharma identity

First transplant of an entire human eye performed

Dobbs anniversary: the lost opportunity of abortion as health care

State of the Union pitch: Bigger Medicare drug price negotiations

In age of alternative facts, a scholarly course on calling out crap

Ohio still needs to do more to protect the right to abortion

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Carbon Health diabetes program, a test of data

leisure time

Lack of health data on LGBTQ+ people has serious consequences

Medical school prerequisites are outdated

Fetal cell organoids grown from amniotic fluid, study finds

IVF doctors demand details after CooperSurgical lawsuit

What is STAT's opinion section for?

Biden's 'march

hotspot

knowledge

focus

leisure time